secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001193125-26-215752
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed
--------------------------------------------------------------------------------

- Total net revenue $34.7M vs $38.9M YoY; Acute Care franchise up 32% led by ZYNRELEF (+27%) and APONVIE (+50%).
- Oncology net revenue $21.1M (-26.3% YoY) as CINVANTI declined 20.2% and SUSTOL wind-down continued.
- Reaffirmed FY2026 guidance: net revenue $173-183M and Adjusted EBITDA $10-20M; cash $44.8M.
- Settled CINVANTI patent litigation with Baxter; case dismissed April 28, 2026.
- Sales force expansion on track for Q3 2026; ZYNRELEF prefilled syringe program on schedule with stability data in Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/0001193125-26-215752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/hrtx-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-215752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer